Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

Strategic launch planning: familiar framework, new mindset

By James Aird

- PMLiVE

Diane DiGangi Trench appointed as country head of Sandoz UK

Previously, DiGangi Trench held the position of vice-president, market access and patient services at Sandoz in the US

- PMLiVE

Prothena achieves $60m milestone as part of Roche collaboration

Milestone reached as first patient doses in phase 2b trial of prasinezumab in early Parkinson's disease patients

- PMLiVE

FREE webinar: Is there a doctor in the house?

Join the discussion on the value of having a medical degree for a career in medical communications

Porterhouse Medical Group

- PMLiVE

EU asks AZ to deliver 120 million COVID-19 vaccines by the end of June

The EU has launched a new lawsuit against the drugmaker which could result in financial sanctions

- PMLiVE

Novavax announces further delays for regulatory filings of COVID-19 vaccine

The company had been aiming for FDA emergency approval in May

The power of communication: Engaging diverse groups in healthcare

Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...

Page & Page Health

- PMLiVE

Avoiding A Series of Unfortunate Events: launch lessons from lockdown

Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story

- PMLiVE

Origins Insights wins the “Best Patient-Centric Approach” award at the BHBIA BOBI Awards 2021

Origins Insights thrilled to be named as winners at the BHBIA BOBI Awards 2021

Origins – The Patient Focused Specialists

- PMLiVE

Lilly signs $1.25bn collaboration deal with MiNA Therapeutics

Lilly will pay MiNA $25m upfront as well as milestones payments of up to a total of $245m per target

- PMLiVE

AZ, Amgen file first-in-class asthma drug with the FDA

Submission is based on positive results from the companies’ PATHFINDER clinical programme

- PMLiVE

Biogen and Capsigen to collaborate on gene therapies

Biogen will gain exclusive right for undisclosed number of CNS and neuromuscular disease targets

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links